Panel Title: Intellectual Property in AI and data technologies
Panel Date: 14 October 2020
The UK Bioscience Forum will return in October 2020 as a two day virtual event, with the theme emerging data technologies.
Recent years have seen an explosion of emerging data technologies in the biotech sector. Many of these address long-standing challenges in the industry, offering the potential to reduce the time and cost of drug discovery, and to target beyond what was previously possible. But new opportunities bring new challenges. Ethical harnessing of data, access to and governance of data, skills and interoperability all provide significant hurdles.
The competing demands of data creation, data protection and data provision and acquisition pull data IP practice in different ways. How can we manage these competing demands to produce a result that is ultimately most beneficial for patients and the sector? Find out more at the panel discussion on Intellectual Property in AI and data technologies.
Mogrify® has developed a proprietary direct cellular conversion technology that utilizes a systematic big-data approach (Rackham et al., Nature Genetics, 2016). By deploying next-generation sequencing and gene regulatory data, the platform enables the prediction of the transcription factors (or small molecules) required to produce (ex vivo or in vivo) any target cell type from any source cell type.